Serum biomarkers confirming stable remission in inflammatory bowel disease

Abstract Crohn's disease (CD) and ulcerative colitis (UC) have a chronic-remittent course. Optimal management of inflammatory bowel diseases (IBD) relies on early intervention, treat-to-target strategies and a tight disease control. However, it is challenging to assess the risk of relapses in i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Christoph Kessel, Miha Lavric, Toni Weinhage, Markus Brueckner, Sytze de Roock, Jan Däbritz, Jakob Weber, Sebastiaan J. Vastert, Dirk Foell
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/37b17cb0522542b7b2404374a3412388
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:37b17cb0522542b7b2404374a3412388
record_format	dspace
spelling	oai:doaj.org-article:37b17cb0522542b7b2404374a34123882021-12-02T16:35:56ZSerum biomarkers confirming stable remission in inflammatory bowel disease10.1038/s41598-021-86251-w2045-2322https://doaj.org/article/37b17cb0522542b7b2404374a34123882021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-86251-whttps://doaj.org/toc/2045-2322Abstract Crohn's disease (CD) and ulcerative colitis (UC) have a chronic-remittent course. Optimal management of inflammatory bowel diseases (IBD) relies on early intervention, treat-to-target strategies and a tight disease control. However, it is challenging to assess the risk of relapses in individual patients. We investigated blood-based biomarkers for the confirmation of disease remission in patients with IBD. We retrospectively analyzed samples of 40 IBD patients (30 UC, 10 CD) enrolled in a tight-control follow-up study. Half of the patients had a flare during follow up. Serum was analyzed for S100A12 as well as S100A8/A9 and for 50 further biomarkers in a bead-based multiplex assay. The concentrations of 9 cytokines/chemokines and S100A8/A9 significantly differed in IBD patients with unstable remission (before flares) when compared to IBD patients with stable remission. Although the number of patients was small, ROC curve analyses revealed a number of biomarkers (IL-1β, IL-1RA, IL-8, IL13, IL-15, IL-21, IL-25, IFN-β, CXCL9, CXCL10, CXCL11, Galectin-1, G-CSF and S100A8/A9) that were elevated in patients with later occurring relapses. While earlier studies on peripheral biomarkers in IBD are limited to only few analytes, our study using a broad screening approach identified serum biomarkers with the potential to indicate unstable disease control in IBD, which may help to steer individual therapies to maintain remission.Christoph KesselMiha LavricToni WeinhageMarkus BruecknerSytze de RoockJan DäbritzJakob WeberSebastiaan J. VastertDirk FoellNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Christoph Kessel Miha Lavric Toni Weinhage Markus Brueckner Sytze de Roock Jan Däbritz Jakob Weber Sebastiaan J. Vastert Dirk Foell Serum biomarkers confirming stable remission in inflammatory bowel disease
description	Abstract Crohn's disease (CD) and ulcerative colitis (UC) have a chronic-remittent course. Optimal management of inflammatory bowel diseases (IBD) relies on early intervention, treat-to-target strategies and a tight disease control. However, it is challenging to assess the risk of relapses in individual patients. We investigated blood-based biomarkers for the confirmation of disease remission in patients with IBD. We retrospectively analyzed samples of 40 IBD patients (30 UC, 10 CD) enrolled in a tight-control follow-up study. Half of the patients had a flare during follow up. Serum was analyzed for S100A12 as well as S100A8/A9 and for 50 further biomarkers in a bead-based multiplex assay. The concentrations of 9 cytokines/chemokines and S100A8/A9 significantly differed in IBD patients with unstable remission (before flares) when compared to IBD patients with stable remission. Although the number of patients was small, ROC curve analyses revealed a number of biomarkers (IL-1β, IL-1RA, IL-8, IL13, IL-15, IL-21, IL-25, IFN-β, CXCL9, CXCL10, CXCL11, Galectin-1, G-CSF and S100A8/A9) that were elevated in patients with later occurring relapses. While earlier studies on peripheral biomarkers in IBD are limited to only few analytes, our study using a broad screening approach identified serum biomarkers with the potential to indicate unstable disease control in IBD, which may help to steer individual therapies to maintain remission.
format	article
author	Christoph Kessel Miha Lavric Toni Weinhage Markus Brueckner Sytze de Roock Jan Däbritz Jakob Weber Sebastiaan J. Vastert Dirk Foell
author_facet	Christoph Kessel Miha Lavric Toni Weinhage Markus Brueckner Sytze de Roock Jan Däbritz Jakob Weber Sebastiaan J. Vastert Dirk Foell
author_sort	Christoph Kessel
title	Serum biomarkers confirming stable remission in inflammatory bowel disease
title_short	Serum biomarkers confirming stable remission in inflammatory bowel disease
title_full	Serum biomarkers confirming stable remission in inflammatory bowel disease
title_fullStr	Serum biomarkers confirming stable remission in inflammatory bowel disease
title_full_unstemmed	Serum biomarkers confirming stable remission in inflammatory bowel disease
title_sort	serum biomarkers confirming stable remission in inflammatory bowel disease
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/37b17cb0522542b7b2404374a3412388
work_keys_str_mv	AT christophkessel serumbiomarkersconfirmingstableremissionininflammatoryboweldisease AT mihalavric serumbiomarkersconfirmingstableremissionininflammatoryboweldisease AT toniweinhage serumbiomarkersconfirmingstableremissionininflammatoryboweldisease AT markusbrueckner serumbiomarkersconfirmingstableremissionininflammatoryboweldisease AT sytzederoock serumbiomarkersconfirmingstableremissionininflammatoryboweldisease AT jandabritz serumbiomarkersconfirmingstableremissionininflammatoryboweldisease AT jakobweber serumbiomarkersconfirmingstableremissionininflammatoryboweldisease AT sebastiaanjvastert serumbiomarkersconfirmingstableremissionininflammatoryboweldisease AT dirkfoell serumbiomarkersconfirmingstableremissionininflammatoryboweldisease
_version_	1718383683965026304

Serum biomarkers confirming stable remission in inflammatory bowel disease

Ejemplares similares